OncLive
Andrew Kin, M.D., hematologist and medical oncologist, member of the Bone Marrow & Stem Cell Transplant, Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams, discusses how BCMA-targeted therapies have shifted how relapsed/refractory multiple myeloma is treated, limitations of using these agents, and the approval of teclistamab.
Read the article here.